Klein and Associates — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$1,126	2
2023	Research	$1,696	2
2022	Research	$168,582	180
2021	Research	$104,702	15
2020	Research	$102,799	17
2019	Research	$99,078	9

Breakdown

Who paid Research payments · program years 2019–2024

AstraZeneca UK Limited $228,597 22 payments
Janssen Research & Development, LLC $134,859 178 payments
Novartis Pharmaceuticals Corporation $65,234 3 payments
GlaxoSmithKline, LLC. $49,293 22 payments

Studies the money was for Research payments · program years 2019–2024

The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $213,191 20 payments
Cnto1959psa3004 $129,859 176 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Ankylosing Spondylitis Or Non-Radiographic Axial Spondyloarthritis $60,546 1 payment
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $46,438 20 payments
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE $15,406 2 payments
cnto1959psa3004 a study of guselkumab in participants with active psoriatic arthritis (apex) $5,000 2 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Ankylosing Spo $4,689 2 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $2,855 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.